Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study
European Journal of Cancer · 2026-11 · 248 · 117041
DOI: 10.1016/j.ejca.2026.117041 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von Alice Bernard-Tessier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. Electronic address: alice.bernard-tessier@gust…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Breast Neoplasms, Steroid Synthesis Inhibitors. Die Arbeit nennt 37 Literaturangaben. Gefördert von: MSD Sharp & Dohme GmbH, Merck, Orion Corporation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France. Electronic address: alice.bernard-tessier@gustaveroussy.fr.
- Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
- Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
- Department of Oncology, Tampere University Hospital (TAYS), Tampere, Finland.
- Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
- Department of Biologics, Orion Pharma, Espoo, Finland.
Förderung
- MSD Sharp & Dohme GmbH
- Merck
- Orion Corporation
- Merck Sharp and Dohme United Kingdom
Zitieren
APA
Bernard-Tessier, A., Spanggaard, I., Utriainen, T., Tanner, M., Rohrberg, K., Naoun, N., Ikonen, T., Pohjanjousi, P., Garratt, C., Poehlein, C., & Fizazi, K. (2026). Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study. European Journal of Cancer, 248, 117041. https://doi.org/10.1016/j.ejca.2026.117041
Vancouver
Bernard-Tessier A, Spanggaard I, Utriainen T, Tanner M, Rohrberg K, Naoun N, et al. Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study. European Journal of Cancer. 2026;248:117041. doi:10.1016/j.ejca.2026.117041
BibTeX
@article{BernardTessier2026,
author = {Bernard-Tessier, Alice and Spanggaard, Iben and Utriainen, Tapio and Tanner, Minna and Rohrberg, Kristoffer and Naoun, Natacha and Ikonen, Tarja and Pohjanjousi, Pasi and Garratt, Chris and Poehlein, Christian and Fizazi, Karim},
title = {Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117041},
doi = {10.1016/j.ejca.2026.117041}
}
EUVIMED